BRPI0906681A2 - molécula associada com tumor humano metastático, métodos de detecção de ambos gene ativo e proteína e para interferir com a expressão do gene - Google Patents

molécula associada com tumor humano metastático, métodos de detecção de ambos gene ativo e proteína e para interferir com a expressão do gene

Info

Publication number
BRPI0906681A2
BRPI0906681A2 BRPI0906681-0A BRPI0906681A BRPI0906681A2 BR PI0906681 A2 BRPI0906681 A2 BR PI0906681A2 BR PI0906681 A BRPI0906681 A BR PI0906681A BR PI0906681 A2 BRPI0906681 A2 BR PI0906681A2
Authority
BR
Brazil
Prior art keywords
protein
methods
interfere
detecting
gene
Prior art date
Application number
BRPI0906681-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Lozupone Francesco
Fais Stefano
Original Assignee
Hansabiomed Ou
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hansabiomed Ou filed Critical Hansabiomed Ou
Publication of BRPI0906681A2 publication Critical patent/BRPI0906681A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0906681-0A 2008-01-25 2009-01-26 molécula associada com tumor humano metastático, métodos de detecção de ambos gene ativo e proteína e para interferir com a expressão do gene BRPI0906681A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6245308P 2008-01-25 2008-01-25
US61/062.453 2008-01-25
PCT/EE2009/000001 WO2009092385A1 (en) 2008-01-25 2009-01-26 A new metastatic human tumor associated molecule, methods to detect both activated gene and protein and to interfere with gene expression

Publications (1)

Publication Number Publication Date
BRPI0906681A2 true BRPI0906681A2 (pt) 2019-11-26

Family

ID=40527972

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0906681-0A BRPI0906681A2 (pt) 2008-01-25 2009-01-26 molécula associada com tumor humano metastático, métodos de detecção de ambos gene ativo e proteína e para interferir com a expressão do gene

Country Status (12)

Country Link
US (1) US8097407B2 (https=)
EP (1) EP2245465B1 (https=)
JP (1) JP5752419B2 (https=)
CN (1) CN102016587B (https=)
AU (1) AU2009207926B2 (https=)
BR (1) BRPI0906681A2 (https=)
CA (1) CA2713193C (https=)
ES (1) ES2587055T3 (https=)
MX (1) MX2010008163A (https=)
PL (1) PL2245465T3 (https=)
RU (1) RU2546000C2 (https=)
WO (1) WO2009092385A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120122118A1 (en) * 2008-01-25 2012-05-17 Primm Srl Monclonal antibodies, hybridomas and methods for use
EP2467392A4 (en) * 2009-08-17 2013-06-19 Nox Technologies Inc CLONING AND EXPRESSION OF 9-DOMAIN SUPERFAMILY OF ARNOX TRANSMEMBRANE PROTEINS, METHODS AND UTILITY
JP6187939B2 (ja) * 2012-03-08 2017-08-30 学校法人産業医科大学 がんの悪性度の試験方法、ならびに多能性を有する造腫瘍細胞およびその調製方法
WO2015185730A2 (en) * 2014-06-06 2015-12-10 Hansabiomed Ou Exosomal biomarkers
CN105675378A (zh) * 2014-11-18 2016-06-15 上海张江转化医学研发中心有限公司 一种简单的分离单个循环肿瘤细胞的方法和装置
JP6573351B2 (ja) 2017-05-29 2019-09-11 国立大学法人神戸大学 検出対象の分析用センサ作製用基材、検出対象の分析用センサ、及び検出対象の分析法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030175787A1 (en) * 1997-10-28 2003-09-18 Incyte Corporation Vesicle membrane proteins
US20030008356A1 (en) * 1998-08-07 2003-01-09 Ono Pharmaceutical Co., Ltd. Novel polypeptide, a cDNA encoding the same, and use of it
WO2000008056A1 (fr) * 1998-08-07 2000-02-17 Ono Pharmaceutical Co., Ltd. NOUVEAU POLYPEPTIDE, ADNc LE CODANT ET SON UTILISATION
US20070224201A1 (en) * 2002-10-02 2007-09-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2005108415A2 (en) * 2004-04-30 2005-11-17 Biogen Idec Ma Inc. Membrane associated molecules
WO2006110593A2 (en) * 2005-04-07 2006-10-19 Macrogenics, Inc. Biological targets for the diagnosis, treatment and prevention of cancer

Also Published As

Publication number Publication date
EP2245465A1 (en) 2010-11-03
AU2009207926B2 (en) 2014-06-19
PL2245465T3 (pl) 2016-11-30
US20090191222A1 (en) 2009-07-30
RU2546000C2 (ru) 2015-04-10
EP2245465B1 (en) 2016-05-18
MX2010008163A (es) 2011-04-26
JP5752419B2 (ja) 2015-07-22
ES2587055T3 (es) 2016-10-20
JP2011511625A (ja) 2011-04-14
US8097407B2 (en) 2012-01-17
CN102016587B (zh) 2015-05-13
CA2713193A1 (en) 2009-07-30
RU2010135525A (ru) 2012-02-27
WO2009092385A1 (en) 2009-07-30
CA2713193C (en) 2018-01-02
CN102016587A (zh) 2011-04-13
AU2009207926A1 (en) 2009-07-30

Similar Documents

Publication Publication Date Title
MY183404A (en) Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
BRPI0906681A2 (pt) molécula associada com tumor humano metastático, métodos de detecção de ambos gene ativo e proteína e para interferir com a expressão do gene
BR112015010740A2 (pt) Agentes para tratamento de doenças cancerosas expressando claudina
BR112015008255A2 (pt) método para o diagnóstico, prognóstico e tratamento de metástase de câncer de próstata
MX346973B (es) Anticuerpos especificos de tumores y usos para los mismos.
EP3722810A3 (en) Molecular profiling of tumors
WO2009015050A3 (en) Gene expression profile for predicting ovarian cancer patient survival
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft
BR112012026213A2 (pt) pirrolobenzodiazepinas e conjugados das mesmas
WO2005116259A3 (en) Use of gene expression profiling to predict survival in cancer patient
IL207637A (en) Choosing a Breast Cancer Remedy Using Antibody-Based Arrays
MX377405B (es) Compuestos para el tratamiento de cáncer.
MX2007014132A (es) Compuestos de diarilhidantoina.
EA200970891A1 (ru) Генетические варианты chr2 и chr16 в качестве маркеров для применения при оценке риска, диагностировании, прогнозировании и лечении рака молочной железы
UY33334A (es) Proteina de fusion Robol-Fc y su utilizacion en el tratamiento de tumores .
MX2014000292A (es) Usos de inhibidores etiquetados hsp90.
IL182423A0 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
AR069393A1 (es) Inhibicion del receptor para la proteina estimulante del macrofago (ron) y metodos para el tratamiento del mismo
CL2008000785A1 (es) Compuestos derivados de 4-((7,7-difluoro-5-metil-6-oxo-6,7,8,9-tetrahidro-5h-pirimido[4,5-b][1,4]diazepin-2-il)amino)-3-metoxibenzamida; compuesto intermediario; composicion farmaceutica, utiles para tratar el cancer.
BR112015032542A2 (pt) peptídeos e peptídeos miméticos em tratamentos e usos de combinação para subpopulações de pacientes com câncer
WO2012154567A3 (en) Human invasion signature for prognosis of metastatic risk
ATE553382T1 (de) Verwendungen von krebsspezifischen glykanen
NO20090174L (no) Genfamilie (LBFL313) assosiert med kreft i bukspyttkjertel
WO2008060945A3 (en) Diagnosis and treatment of breast cancer
WO2006133361A3 (en) Use of gene expression profiling to predict survival in cancer patient

Legal Events

Date Code Title Description
B25C Requirement related to requested transfer of rights

Owner name: HANSABIOMED OU (EE)

Free format text: A FIM DE ATENDER A TRANSFERENCIA, REQUERIDA ATRAVES DA PETICAO NO 870190033505 DE 08/04/2019, E NECESSARIO APRESENTAR A TRADUCAO JURAMENTADA DO DOCUMENTO, ALEM DA GUIA DE CUMPRIMENTO DE EXIGENCIA.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: EXOSOMICS SIENA S.P.A. (IT)

B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: EXOSOMICS SIENA S.P.A. (IT)

Free format text: A FIM DE ATENDER A ALTERACAO DE NOME REQUERIDA ATRAVES DA PETICAO NO 870200003629, DE 09/01/2020, E NECESSARIO APRESENTAR A TRADUCAO JURAMENTADA DO DOCUMENTO, ALEM DA GUIA DE CUMPRIMENTO DE EXIGENCIA.

B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: EXOSOMICS SIENA S.P.A. (IT)

Free format text: A FIM DE ATENDER A(S) ALTERACAO(OES) DE NOME REQUERIDA(S) ATRAVES DA PETICAO NO870200003629 DE 09/01/2020 E MEDIANTE O PROTOCOLO DA PETICAO 870200047390 DE 15/04/2020, ENECESSARIO:1. APRESENTAR TRADUCAO JURAMENTADA QUE CONTENHA O NUMERO DA TRADUCAO, O NUMERO DO LIVRODE TRADUCOES E DAS RESPECTIVAS PAGINAS, O TEXTO DE ABERTURA IDENTIFICANDO O TRADUTORPUBLICO, A ASSINATURA DO TRADUTOR E DEMAIS ELEMENTOS QUE SE FIZEREM NECESSARIOS,CONFORME O DECRETO NO 13.609, DE 21 DE OUTUBRO DE 1943;2. APRESENTAR GRU REFERENTE AO CUMPRIMENTO DA PRESENTE EXIGENCIA.

B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: EXOSOMICS SIENA S.P.A. (IT)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B25E Requested change of name of applicant rejected

Owner name: EXOSOMICS SIENA S.P.A. (IT)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: EXOSOMICS SIENA S.P.A. (IT)

Free format text: A FIM DE ATENDER A ALTERACAO DE NOME E SEDE REQUERIDAS ATRAVES DA PETICAO NO 870200155997, DE 11/12/2020, E NECESSARIO APRESENTAR MAIS UMA GUIA DE RECOLHIMENTO, CODIGO 248, RELATIVA AO SEGUNDO SERVICO SOLICITADO. ALEM DISSO, E PRECISO APRESENTAR A GUIA DE CUMPRIMENTO DE EXIGENCIA.

B25D Requested change of name of applicant approved

Owner name: EXOSOMICS S.P.A. (IT)

B25G Requested change of headquarter approved

Owner name: EXOSOMICS S.P.A. (IT)

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.